News
12-03-2009, 02:30 AM
ImmunoCellular Therapeutics, Ltd., a biotechnology company that is focused on the development of novel immune-based cancer therapies, announced today that it has entered into an option agreement with The University of Texas M. D. Anderson Cancer Center relating to an immunotherapy targeting cancer stem cells (CSCs) which has demonstrated in pre-clinical animal models significant abilities to target and destroy CSCs.
More... (http://www.news-medical.net/news/20091203/ImmunoCellular-Therapeutics-options-immunotherapy-targeting-CSCs-using-abnormal-Notch-and-Numb-pathways.aspx)
More... (http://www.news-medical.net/news/20091203/ImmunoCellular-Therapeutics-options-immunotherapy-targeting-CSCs-using-abnormal-Notch-and-Numb-pathways.aspx)